Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome DOI Creative Commons
Michail Diakosavvas, Oyinlola Oyebode, Priya Bhide

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: March 6, 2025

Polycystic Ovary Syndrome (PCOS) affects 10-15% of women reproductive age and is associated with a heightened risk metabolic morbidity, exacerbated by insulin resistance obesity. Current weight management strategies have limited effectiveness in reducing morbidity this subgroup. This review examines the potential Intensive Weight Management Programmes (IWMPs) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to reduce risks PCOS, drawing from studies both PCOS-specific related populations. IWMPs, including total diet replacement, achieve substantial sustained loss (5-15% over 1-5 years) individuals obesity type 2 diabetes, alongside improvements markers like blood pressure glycemic control. GLP-1 RAs, particularly semaglutide, similarly deliver significant (10-15% 1-2 benefits. While there data specifically targeting emerging suggest RAs can improve weight, sensitivity, menstrual regularity group. However, evidence for interventions PCOS remains insufficient. Women face unique challenges, resistance, compounded IWMPs are promising interventions, their populations Addressing research gap through targeted trials essential outcomes affected disorders.

Language: Английский

EFFECTS OF CARBOHYDRATE REDUCTION DIET ASSOCIATED WITH STRENGTH TRAINING ON CLINICAL SIGNS OF WOMEN WITH POLYCYSTIC OVARIAN SYNDROME: RANDOMIZED CLINICAL TRIAL DOI
Laura Colonetti, Maria Laura Rodrigues Uggioni, Gabriele da Silveira Prestes

et al.

Nutrition, Journal Year: 2025, Volume and Issue: unknown, P. 112696 - 112696

Published: Jan. 1, 2025

Language: Английский

Citations

0
Long-term implications of polycystic ovary syndrome (PCOS): An in-depth study on associated health risks and complications DOI Creative Commons
Sanjeev Kumar Yadav,

Alka Rai,

Akanksha Gupta

et al.

Indian Journal of Obstetrics and Gynecology Research, Journal Year: 2025, Volume and Issue: 12(1), P. 74 - 78

Published: Feb. 15, 2025

Polycystic ovary syndrome (PCOS) is a most common clinical-hormonal women-affecting disorder, often leading to chronic health issues beyond reproductive challenges. Women with PCOS experience irregular menstrual cycles along elevated androgen levels; however, also associated high risk of clinical-conditions such as Type 1 and 2 diabetes, cardiovascular disease (CVD) due underlying metabolic disturbances. This study investigates the risks complications PCOS, including disease, fertility problems, aiming develop improved management strategies. cross-sectional was performed 200 PCOS-diagnosed women three hundred age-matched controls without PCOS. Data collected from different sources like- Medical records, Laboratory tests, Interviews patients, Body mass index(BMI), Blood glucose, Insulin levels, Cholesterol profile, C-reactive protein(CRP), Menstrual history, Cardiovascular markers. Statistical analysis compare two groups through SPSS 20.0. The revealed significantly higher rates insulin resistance (72% vs. 25%) diabetes(35% 10%) among PCOS-women. Additionally, CVD factors hypertension (45% 20%), abnormal cholesterol levels (60% 30%), CRP were more prevalent in Group I. Fertility I (with 80% experiencing anovulation 50% reporting infertility) compared 10% II. significant clinical-risk factor for many types diseases like Diabetes, CVD, infertility, etc. Effective requires comprehensive approach involving lifestyle modifications, medications, regular screening monitoring reduce improve

Language: Английский

Citations

0
The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment DOI Creative Commons

Arghavan Ghafari,

Malihe Maftoohi,

Mohammadamin Eslami Samarin

et al.

Endocrine and Metabolic Science, Journal Year: 2025, Volume and Issue: unknown, P. 100228 - 100228

Published: March 1, 2025

Language: Английский

Citations

0
Risk of Mental Disorders in Polycystic Ovary Syndrome: Retrospective Cohort Study of a Korean Nationwide Population-Based Cohort DOI Creative Commons

Young-Jin Kim,

Kyung‐Hee Chae, Sukil Kim

et al.

International Journal of Women s Health, Journal Year: 2025, Volume and Issue: Volume 17, P. 627 - 638

Published: March 1, 2025

Polycystic Ovary Syndrome (PCOS) is one of the most common gynecological endocrine conditions, affecting both physical and mental health, quality life women. PCOS was associated with diverse disorders but studies in Korean populations were limited. This study aims to investigate risk patients Korea. We evaluated five using health insurance billing data from National Health Insurance Corporation. selected 188,973 412,022 control individuals. Prevalence, cumulative incidence, Hazard ratios (HR) calculated for each disorder. found have increased prevalence depressive (Odds (OR) 1.208[1.185-1.232]), bipolar (OR 1.403[1.330-1.479]), anxiety 1.089[1.064-1.114]); however, also had lower schizophrenia 0.686[0.638-0.737]) sleep disorder 0.911[0.888-0.935]). The exhibited a significantly greater HR (adjusted 1.244[1.148-1.347]), 1.502[1.139-1.981]), 1.147[1.050-1.252]), 1.228[1.112-1.356]). Our results suggest that disorders, disorders. supports international guidelines recommend screening

Language: Английский

Citations

0
Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome DOI Creative Commons
Michail Diakosavvas, Oyinlola Oyebode, Priya Bhide

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: March 6, 2025

Polycystic Ovary Syndrome (PCOS) affects 10-15% of women reproductive age and is associated with a heightened risk metabolic morbidity, exacerbated by insulin resistance obesity. Current weight management strategies have limited effectiveness in reducing morbidity this subgroup. This review examines the potential Intensive Weight Management Programmes (IWMPs) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to reduce risks PCOS, drawing from studies both PCOS-specific related populations. IWMPs, including total diet replacement, achieve substantial sustained loss (5-15% over 1-5 years) individuals obesity type 2 diabetes, alongside improvements markers like blood pressure glycemic control. GLP-1 RAs, particularly semaglutide, similarly deliver significant (10-15% 1-2 benefits. While there data specifically targeting emerging suggest RAs can improve weight, sensitivity, menstrual regularity group. However, evidence for interventions PCOS remains insufficient. Women face unique challenges, resistance, compounded IWMPs are promising interventions, their populations Addressing research gap through targeted trials essential outcomes affected disorders.

Language: Английский

Citations

0